Lumos Diagnostics receives FDA EUA for ViraDx Rapid POC Test
Lumos Diagnostics (ASX: LDX) has announced that its ViraDx test has been granted Emergency Use Authorization (EUA) and a CLIA Waiver by the US Food and Drug Administration (FDA). The rapid Point-of-Care (POC) test can simultaneously detect COVID-19, influenza A, and influenza B viruses and provides results within 15 minutes. The test received Health Canada’s […]